Department of Oncology, Sheba Medical Center, Tel-Hashomer, Israel; Tel-Aviv University, Tel-Aviv, Israel.
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Clin Colorectal Cancer. 2019 Sep;18(3):226-230.e2. doi: 10.1016/j.clcc.2019.04.004. Epub 2019 Apr 13.
Previous small retrospective studies have suggested a benefit, mainly in preventing local recurrence, for postoperative radiation in nonmetastatic pathologic stage T4 colon cancers in patients who did not receive adjuvant chemotherapy. Current guidelines recommend postoperative radiation in nonmetastatic T4 colon cancers with penetration to a fixed structure, as well as for all patients with positive surgical margins. We aimed to assess the survival benefit of postoperative radiation in individuals with T4 colon cancers who received adjuvant chemotherapy.
Using the National Cancer Data Base (2004-2014), we identified 20,967 and 5882 individuals with nonmetastatic pathologic stage T4 colon cancer treated with adjuvant chemotherapy who had negative or positive surgical margins, respectively. We used multivariate Cox regression to evaluate the effect of postoperative radiation on overall survival. In a secondary analysis, we stratified individuals according to chemotherapy intensity, pathologic N stage, and primary tumor location.
Postoperative radiation did not improve overall survival in individuals with positive surgical margins (hazard ratio = 1.05 [95% CI, 0.96-1.16]). This lack of survival benefit was noted regardless of chemotherapy regimen used, with adjusted hazard ratios of 1.11 (95% CI, 0.94-1.31) and 0.96 (0.85-1.09) for single-agent and doublet chemotherapy, respectively. Similarly, pathologic N stage and primary tumor location did not affect survival. In individuals with negative surgical margins, there was a detrimental effect for postoperative radiation, with an adjusted hazard ratio of 1.19 (95% CI, 1.10-1.29).
Postoperative radiation did not improve overall survival in individuals with pathologic stage T4 colon cancer who had either negative or positive surgical margins and who received adjuvant chemotherapy.
先前的小型回顾性研究表明,对于未接受辅助化疗的非转移性病理 T4 期结肠癌患者,术后放疗可主要预防局部复发。目前的指南建议对穿透固定结构的非转移性 T4 结肠癌以及所有切缘阳性的患者进行术后放疗。我们旨在评估接受辅助化疗的 T4 结肠癌患者接受术后放疗的生存获益。
利用国家癌症数据库(2004-2014 年),我们分别确定了 20967 例和 5882 例接受辅助化疗且切缘阴性或阳性的非转移性病理 T4 结肠癌患者。我们使用多变量 Cox 回归评估术后放疗对总生存的影响。在二次分析中,我们根据化疗强度、病理 N 分期和原发肿瘤位置对患者进行分层。
术后放疗并未改善切缘阳性患者的总生存(风险比=1.05[95%CI,0.96-1.16])。这种生存获益缺失与化疗方案无关,单药化疗和双药化疗的调整后风险比分别为 1.11(95%CI,0.94-1.31)和 0.96(0.85-1.09)。同样,病理 N 分期和原发肿瘤位置也不影响生存。对于切缘阴性的患者,术后放疗有不利影响,调整后风险比为 1.19(95%CI,1.10-1.29)。
对于接受辅助化疗且病理分期为 T4 结肠癌且切缘阴性或阳性的患者,术后放疗并未改善其总体生存。